$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000106282223000024 Filed on May 04, 2023

Income Statement

Concept	2023 Q1
Revenue	$24.00K
YoY Change	-35.14%
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$24.00K
YoY Change
Gross Profit Margin	100.0%
Selling, General & Admin	$19.14M
YoY Change	125.42%
% of Gross Profit	79750.0%
Research & Development	$12.03M
YoY Change	-19.43%
% of Gross Profit	50108.33%
Depreciation & Amortization	$112.0K
YoY Change	2.75%
% of Gross Profit	466.67%
Operating Expenses	-$31.17M
YoY Change	-233.09%
Operating Profit	-$31.14M
YoY Change	33.2%
Interest Expense	$1.821M
YoY Change	1555.45%
% of Operating Profit
Other Income/Expense, Net	$1.029M
YoY Change	7250.0%
Pretax Income	-$31.93M
YoY Change	36.03%
Income Tax
% Of Pretax Income
Net Earnings	-$31.93M
YoY Change	36.03%
Net Earnings / Revenue	-133058.33%
Basic Earnings Per Share	-$0.17
Diluted Earnings Per Share	-$0.17
COMMON SHARES
Basic Shares Outstanding	188.7M shares
Diluted Shares Outstanding	189.0M shares

Balance Sheet

Concept	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$105.9M
YoY Change	22.47%
Cash & Equivalents	$26.00M
Short-Term Investments	$79.94M
Other Short-Term Assets	$3.348M
YoY Change	76.96%
Inventory
Prepaid Expenses
Receivables	$261.0K
Other Receivables	$0.00
Total Short-Term Assets	$109.5M
YoY Change	23.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.207M
YoY Change	93.26%
Goodwill	$44.54M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.420M
YoY Change	211.35%
Total Long-Term Assets	$53.17M
YoY Change	11.36%
TOTAL ASSETS
Total Short-Term Assets	$109.5M
Total Long-Term Assets	$53.17M
Total Assets	$162.7M
YoY Change	19.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.31M
YoY Change	10.62%
Accrued Expenses	$10.06M
YoY Change	4.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.37M
YoY Change	7.75%
LONG-TERM LIABILITIES
Long-Term Debt	$48.85M
YoY Change	108.05%
Other Long-Term Liabilities	$5.454M
YoY Change	396.72%
Total Long-Term Liabilities	$54.30M
YoY Change	120.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.37M
Total Long-Term Liabilities	$54.30M
Total Liabilities	$74.67M
YoY Change	71.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.622B
YoY Change	7.31%
Common Stock	$190.0K
YoY Change	26.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.885M
YoY Change	39.98%
Treasury Stock Shares	868.0K shares
Shareholders Equity	$88.05M
YoY Change
Total Liabilities & Shareholders Equity	$162.7M
YoY Change	19.49%

Cashflow Statement

Concept	2023 Q1
OPERATING ACTIVITIES
Net Income	-$31.93M
YoY Change	36.03%
Depreciation, Depletion And Amortization	$112.0K
YoY Change	2.75%
Cash From Operating Activities	-$31.61M
YoY Change	34.98%
INVESTING ACTIVITIES
Capital Expenditures	$248.0K
YoY Change	226.32%
Acquisitions
YoY Change
Other Investing Activities	$12.34M
YoY Change	-384.88%
Cash From Investing Activities	$12.09M
YoY Change	-374.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$824.0K
YoY Change	-103.54%
NET CHANGE
Cash From Operating Activities	-$31.61M
Cash From Investing Activities	$12.09M
Cash From Financing Activities	-$824.0K
Net Change In Cash	-$20.34M
YoY Change	347.61%
FREE CASH FLOW
Cash From Operating Activities	-$31.61M
Capital Expenditures	$248.0K
Free Cash Flow	-$31.86M
YoY Change	35.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-30111
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Lexicon Pharmaceuticals, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	76-0474169
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2445 Technology Forest Blvd.
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	11th Floor
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	The Woodlands
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77381
CY2023Q1	dei	City Area Code CityAreaCode	281
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	863-3000
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
CY2023Q1	dei	Trading Symbol TradingSymbol	LXRX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	189561819	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26001000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46345000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	79936000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	92012000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	261000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	3348000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2481000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	109546000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	140866000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4096000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3984000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2207000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2071000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	44543000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	44543000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6420000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6819000	usd
CY2023Q1	us-gaap	Assets Assets	162716000	usd
CY2022Q4	us-gaap	Assets Assets	194299000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10311000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10395000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10060000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12777000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	20371000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23172000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48845000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48579000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5454000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5424000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	74670000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	77175000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	190430000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	189214000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	190000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	189000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1712558000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1709144000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1621654000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1589720000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-163000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-428000	usd
CY2023Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	868000	shares
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	488000	shares
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	2885000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2061000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	88046000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	117124000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	162716000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	194299000	usd
CY2023Q1	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	24000	usd
CY2022Q1	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	37000	usd
CY2023Q1	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1203000	usd
CY2022Q1	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1032000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12026000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14926000	usd
CY2023Q1	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	2212000	usd
CY2022Q1	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	1740000	usd
CY2023Q1	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	19140000	usd
CY2022Q1	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	8491000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	-31166000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	23417000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-31142000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-23380000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1821000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	110000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1029000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	14000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-31934000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-23476000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	189014000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	149150000	shares
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	265000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-27000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31669000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23503000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	113595000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2772000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	698000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	0	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	864000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-23476000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-27000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	92698000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	117124000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3415000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	824000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	265000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	88046000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-31934000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-23476000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	112000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	109000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3415000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2772000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	265000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	25000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	234000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	867000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-273000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-400000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-207000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2770000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3308000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31613000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23421000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	248000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	76000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	28864000	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	17816000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	41205000	usd
CY2022Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	13484000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12093000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4408000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	824000	usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	864000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	24148000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-824000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23284000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20344000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4545000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46345000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64065000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26001000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59520000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1556000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	85000	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	698	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	0	usd
CY2022Q1	us-gaap	Treasury Stock Carrying Basis TreasuryStockCarryingBasis	6321	usd
CY2023Q1	us-gaap	Business Exit Costs1 BusinessExitCosts1	0	usd
CY2022Q1	us-gaap	Business Exit Costs1 BusinessExitCosts1	1500	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span>
CY2023Q1	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3937000	usd
CY2022Q4	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	3252000	usd
CY2023Q1	lxrx	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	4348000	usd
CY2022Q4	lxrx	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	7830000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	484000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	404000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	10060000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	12777000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	46345000	usd
CY2022Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	26001000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	79936000	usd
CY2023Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	105937000	usd
CY2022Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	92012000	usd
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	138357000	usd
CY2022Q1	lxrx	Oxford Loan Facility OxfordLoanFacility	150000000	usd
CY2022Q1	lxrx	Term Loan A TermLoanA	25000000	usd
CY2022Q4	lxrx	Term Loan B TermLoanB	25000000	usd
CY2022Q1	lxrx	Term Loan A Warrants Number TermLoanAWarrantsNumber	420673	shares
CY2022Q1	lxrx	Term Loan A Warrant Exercise Price TermLoanAWarrantExercisePrice	2.08
CY2022Q4	lxrx	Term Loan A Warrants Number TermLoanAWarrantsNumber	224128	shares
CY2022Q4	lxrx	Term Loan A Warrant Exercise Price TermLoanAWarrantExercisePrice	1.95
CY2022Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0790
CY2022Q1	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.0801
CY2023Q1	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.1257
CY2023Q1	lxrx	Final Payment With No Extention FinalPaymentWithNoExtention	0.06	rate
CY2023Q1	lxrx	Final Payment With Extention FinalPaymentWithExtention	0.07	rate
CY2022Q1	lxrx	Term Loan A Final Payment TermLoanAFinalPayment	1500000	usd
CY2023Q1	lxrx	Term Loan A Debt Discount TermLoanADebtDiscount	4200000	usd
CY2023Q1	lxrx	Term Loan A Interest Expense TermLoanAInterestExpense	1800000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	48800000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6400000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6800000	usd
CY2023Q1	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	1300000	usd
CY2023Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	5500000	usd
CY2022Q4	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	1300000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	5400000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	0.4	usd
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	0.1	usd
CY2022Q1	us-gaap	Payments For Rent PaymentsForRent	0.3	usd
CY2023Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P9Y4M24D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P9Y6M
CY2023Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	9.6	rate
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	9.6	rate
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	673000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1378000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1220000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	865000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	881000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	5644000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10661000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3916000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	6745000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1291000	usd
CY2023Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	5454000	usd

Files In Submission

Name	View Source	Status
0001062822-23-000024-index-headers.html	Edgar Link	pending
0001062822-23-000024-index.html	Edgar Link	pending
0001062822-23-000024.txt	Edgar Link	pending
0001062822-23-000024-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
lxrx-20230331.htm	Edgar Link	pending
lxrx-20230331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
lxrx-20230331_cal.xml	Edgar Link	unprocessable
lxrx-20230331_def.xml	Edgar Link	unprocessable
lxrx-20230331_pre.xml	Edgar Link	unprocessable
lxrx-20230331_lab.xml	Edgar Link	unprocessable
lxrx-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2023 Q1 Form 10-Q Financial Statement

#000106282223000024 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2023 Q1 Form 10-Q Financial Statement

#000106282223000024 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx